Prognostic Factors for Patients with Bone-Only Metastasis in Breast Cancer.
10.3349/ymj.2013.54.5.1168
- Author:
Sung Gwe AHN
1
;
Hak Min LEE
;
Sang Hoon CHO
;
Seung Ah LEE
;
Seung Hyun HWANG
;
Joon JEONG
;
Hy De LEE
Author Information
1. Department of Surgery, Yonsei University Medical College, Seoul, Korea. gsjjoon@yuhs.ac
- Publication Type:Original Article
- Keywords:
Breast neoplasm;
bone metastses;
bisphosphonate
- MeSH:
Adult;
Antineoplastic Agents/therapeutic use;
Bone Neoplasms/drug therapy/genetics/*secondary;
Breast Neoplasms/drug therapy/genetics/*pathology;
Female;
Humans;
Middle Aged;
Multivariate Analysis;
Prognosis;
Receptors, Estrogen/genetics;
Receptors, Progesterone/genetics;
Regression Analysis;
Retrospective Studies;
Survival Analysis
- From:Yonsei Medical Journal
2013;54(5):1168-1177
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Bone is the most frequent site of metastasis among breast cancer patients. We investigated prognostic factors affecting survival following bone-only metastasis in breast cancer patients. MATERIALS AND METHODS: The medical records of breast cancer patients who were treated and followed at Gangnam Severance Hospital retrospectively reviewed to identify patients with bone-only metastasis. RESULTS: The median time from the diagnosis of bone-only metastasis to the last follow-up or death was 55.2 [95% confidence interval (CI), 38.6-71.9] months. The Kaplan-Meier overall survival estimate at 10 years for all patients was 34.9%. In the multivariate Cox regression model, bisphosphonate treatment [hazard ratio=0.18; 95% CI, 0.07-0.43], estrogen receptor positivity (hazard ratio=0.51; 95% CI, 0.28-0.94), and solitary bone metastasis (hazard ratio=0.32; 95% CI, 0.14-0.72) were significantly associated with longer overall survival in the bone-only recurrence group. Among the treatment modalities, only bisphosphonate treatment was identified as a significant prognostic factor. CONCLUSION: Identifying the factors influencing breast cancer mortality after bone-only metastasis will help clarify the clinical course and improve the treatment outcome for patients with breast cancer and bone-only metastasis. Bisphosphonates, as a significant prognostic factor, warrant further investigation.
